Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine, Oncological Diagnostics, Research), By Region, And Segment Forecasts, 2024 - 2030

Tumor Profiling Market Size, Share & Trends Analysis Report By Technique (Genomics, Proteomics), By Technology, By Application (Personalized Cancer Medicine, Oncological Diagnostics, Research), By Region, And Segment Forecasts, 2024 - 2030


Tumor Profiling Market Growth & Trends

The global tumor profiling market size is expected to reach USD 21.73 billion by 2030, expanding at a CAGR of 10.3% from 2024 to 2030, according to a new report by Grand View Research, Inc. Rising research in the application of omics sciences in cancer detection is anticipated to influence market growth.

Technological advances in biotechnology have allowed for deeper insights into metabolism and gene expression. These have accelerated the application of advanced techniques such as metabolomics and epigenetics in cancer screening and detection. Thus, demand for cancer tumor/profiling (CTP) techniques is anticipated to witness lucrative growth with the expansion of downstream applications.

Cancer tumor profiling is a potential procedure through which cancer can be detected and studied further to identify the stage, metabolism, and changes in morphology of the tumor. This aids in routine diagnostics as well as therapeutic decision-making. Tumor profiling has significant importance in developing therapies aimed at a specific individual, based on the severity of ailment and genomic build up of the individual.

Enhanced detection and sequencing techniques such as NGS and in-situ hybridization can help speed up the cancer tumor profiling process and are estimated to gain much traction over the coming years. Their high adoption is attributive to accelerated speed in gaining results with minimum resources and greater accuracy.

Tumor Profiling Market Report Highlights
  • Personalized cancer medicine is expected to be the most lucrative application segment for CTP adoption.
  • Owing to difference in usage of and interdependency of functional information from genomic, epigenomic, and metabolomic analysis of cancer cells, it can be expected that these technology segments will grow in tandem with each other and exhibit lucrative growth over the forecast years
  • Asia Pacific is projected to witness substantial growth over the next decade owing to various developments across major economies, with increased focus of dominant players in emerging economies as well
  • Key players include Illumina, Inc.; Qiagen N.V.; Neogenomics Laboratories Inc.; HTG Molecular Diagnostics, Inc.; Genomic Health Inc.; Caris Life Sciences Helomics Corporation; Nanostring Technologies; Oxford Gene Technology; Ribomed Biotechnologies, Inc.; Personal Genome Diagnostics; GenomeDX; Guardant Health; and Foundation Medicine.
Please note The report will be delivered in 2-3 business days upon order notification.


Chapter 1. Methodology and Scope
1.1. Market Segmentation and Scope
1.2. Market Definitions
1.3. Research Methodology
1.3.1. Information Procurement
1.3.2. Information or Data Analysis
1.3.3. Market Formulation & Data Visualization
1.3.4. Data Validation & Publishing
1.4. Research Scope and Assumptions
1.4.1. List of Data Sources
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Tumor Profiling Market Variables, Trends, & Scope
3.1. Market Introduction/Lineage Outlook
3.2. Market Size and Growth Prospects (USD Million)
3.3. Market Dynamics
3.3.1. Market Drivers Analysis
3.3.2. Market Restraints Analysis
3.4. Tumor Profiling Market Analysis Tools
3.4.1. Porter’s Analysis
3.4.1.1. Bargaining power of the suppliers
3.4.1.2. Bargaining power of the buyers
3.4.1.3. Threats of substitution
3.4.1.4. Threats from new entrants
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Economic and Social landscape
3.4.2.3. Technological landscape
3.4.2.4. Environmental landscape
3.4.2.5. Legal landscape
Chapter 4. Tumor Profiling Market: Technique Estimates & Trend Analysis
4.1. Segment Dashboard
4.2. Tumor Profiling Market: Technique Movement Analysis, USD Million, 2023 & 2030
4.3. Genomics
4.3.1. Genomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.4. Proteomics
4.4.1. Proteomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.5. Metabolomics
4.5.1. Metabolomics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
4.6. Epigenetics
4.6.1. Epigenetics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. Tumor Profiling Market: Technology Estimates & Trend Analysis
5.1. Segment Dashboard
5.2. Tumor Profiling Market: Technology Movement Analysis, USD Million, 2023 & 2030
5.3. Sequencing Techniques
5.3.1. Sequencing Techniques Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.2. NGS
5.3.2.1. NGS Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.3. Sanger Sequencing
5.3.3.1. Sanger Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.3.4. Pyro Sequencing
5.3.4.1. Pyro Sequencing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.4. In Situ Hybridization
5.4.1. In Situ Hybridization Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.5. Immunohistochemistry
5.5.1. Immunohistochemistry Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.6. qPCR
5.6.1. qPCR Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
5.7. Microarray
5.7.1. Microarray Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. Tumor Profiling Market: Application Estimates & Trend Analysis
6.1. Segment Dashboard
6.2. Tumor Profiling Market: Application Movement Analysis, USD Million, 2023 & 2030
6.3. Personalized Cancer Medicine
6.3.1. Personalized Cancer Medicine Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.4. Oncological Diagnostics
6.4.1. Oncological Diagnostics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5. Research
6.5.1. Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.2. Cancer Research
6.5.2.1. Cancer Research Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
6.5.3. Biomarker Discovery
6.5.3.1. Biomarker Discovery Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. Tumor Profiling Market: Regional Estimates & Trend Analysis
7.1. Tumor Profiling Market Share, By Region, 2023 & 2030, USD Million
7.2. North America
7.2.1. North America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.2. U.S.
7.2.2.1. U.S. Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.3. Canada
7.2.3.1. Canada Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.2.4. Mexico
7.2.4.1. Mexico Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3. Europe
7.3.1. Europe Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.2. UK
7.3.2.1. UK Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.3. Germany
7.3.3.1. Germany Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.4. France
7.3.4.1. France Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.5. Italy
7.3.5.1. Italy Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.6. Spain
7.3.6.1. Spain Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.7. Denmark
7.3.7.1. Denmark Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.8. Sweden
7.3.8.1. Sweden Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.3.9. Norway
7.3.9.1. Norway Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4. Asia Pacific
7.4.1. Asia Pacific Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.2. China
7.4.2.1. China Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.3. Japan
7.4.3.1. Japan Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.4. India
7.4.4.1. India Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.5. South Korea
7.4.5.1. South Korea Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.6. Australia
7.4.6.1. Australia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.4.7. Thailand
7.4.7.1. Thailand Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5. Latin America
7.5.1. Latin America Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.2. Brazil
7.5.2.1. Brazil Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.5.3. Argentina
7.5.3.1. Argentina Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6. Middle East and Africa
7.6.1. Middle East and Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.2. South Africa
7.6.2.1. South Africa Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.3. Saudi Arabia
7.6.3.1. Saudi Arabia Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.4. UAE
7.6.4.1. UAE Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
7.6.5. Kuwait
7.6.5.1. Kuwait Tumor Profiling Market Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Recent Developments & Impact Analysis by Key Market Participants
8.2. Company Categorization
8.3. Company Heat Map Analysis
8.4. Company Profiles
8.4.1. Illumina, Inc.
8.4.1.1. Participant’s Overview
8.4.1.2. Financial Performance
8.4.1.3. Product Benchmarking
8.4.1.4. Recent Developments/ Strategic Initiatives
8.4.2. QIAGEN
8.4.2.1. Participant’s Overview
8.4.2.2. Financial Performance
8.4.2.3. Product Benchmarking
8.4.2.4. Recent Developments/ Strategic Initiatives
8.4.3. Genomic Health
8.4.3.1. Participant’s Overview
8.4.3.2. Financial Performance
8.4.3.3. Product Benchmarking
8.4.3.4. Recent Developments/ Strategic Initiatives
8.4.4. Neogenomics Inc.
8.4.4.1. Participant’s Overview
8.4.4.2. Financial Performance
8.4.4.3. Product Benchmarking
8.4.4.4. Recent Developments/ Strategic Initiatives
8.4.5. Life Sciences
8.4.5.1. Participant’s Overview
8.4.5.2. Financial Performance
8.4.5.3. Product Benchmarking
8.4.5.4. Recent Developments/ Strategic Initiatives
8.4.6. Oxford Gene Technology
8.4.6.1. Participant’s Overview
8.4.6.2. Financial Performance
8.4.6.3. Product Benchmarking
8.4.6.4. Recent Developments/ Strategic Initiatives
8.4.7. Bruker Spatial Biology, Inc.
8.4.7.1. Participant’s Overview
8.4.7.2. Financial Performance
8.4.7.3. Product Benchmarking
8.4.7.4. Recent Developments/ Strategic Initiatives
8.4.8. Ribomed Biotechnologies Inc.
8.4.8.1. Participant’s Overview
8.4.8.2. Financial Performance
8.4.8.3. Product Benchmarking
8.4.8.4. Recent Developments/ Strategic Initiatives
8.4.9. GenomeDX
8.4.9.1. Participant’s Overview
8.4.9.2. Financial Performance
8.4.9.3. Product Benchmarking
8.4.9.4. Recent Developments/ Strategic Initiatives
8.4.10. Guardant Health
8.4.10.1. Participant’s Overview
8.4.10.2. Financial Performance
8.4.10.3. Product Benchmarking
8.4.10.4. Recent Developments/ Strategic Initiatives
8.4.11. FOUNDATION MEDICINE, INC.
8.4.11.1. Participant’s Overview
8.4.11.2. Financial Performance
8.4.11.3. Product Benchmarking
8.4.11.4. Recent Developments/ Strategic Initiatives

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings